Pharmasset drug goes on the fast track; Numerate and Intellikine call off pact;

 @FierceBiotech: Biotech M&A frenzy shows no sign of slowing. Report | Follow @FierceBiotech

 @JohnCFierce: Dicerna's delivery tech has been the key to early pacts, helped it grab a $25M Series B. Article | Follow @JohnCFierce

> FDA panel backs new epilepsy drug from GSK, Valeant. Story

> The FDA has put Pharmasset's hepatitis C drug, PSI-7977, on its fast track, offering an expedited review to speed development. Story

> Numerate and Intellikine have called off the cancer research collaboration. Report

> Daiichi Sankyo is having a hard time keeping a CEO at Dr. Reddy's. The Indian company, which has been expanding into new drug development, says that Atul Sobti resigned, shortly after he celebrated his first anniversary in the post. Story

> Ann Arbor, MI-based Swift Biosciences has banked a $3 million Series A to fund its work on genetic analysis technology. DFJ Mercury led the round. Release

> Norway's biotech business is getting more positive press. The Independent focuses on promising new cancer therapies now in development. Report

Special Report: Top 5 Medical Device VC Deals, H1 2010

Special Report: Top 10 Generic Drug Companies 2010

And Finally... Researchers in the Faculty of Medicine & Dentistry at the University of Alberta say they are a step closer to a treatment for pulmonary arterial hypertension, a potentially deadly disease. University of Alberta release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.